Avastin for Post-Photocoagulation Macular Edema

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

to evaluate the efficacy of a single intravitreal bevacizumab (IVB) injection, 0.1mL (2.5mg), against panretinal photocoagulation (PRP)-induced macular thickening and visual disturbance in patients with severe nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR) and good vision

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Asociación para Evitar la Ceguera en México
• Treatments: Bevacizumab

Criteria

Inclusion Criteria:

• Patients with Proliferative retinopathy or severe non-proliferative retinopathy

• BCVA of 20/63 or better (56 ETDRS letters

• No history of Macular Edema

• Central Retinal Thickness of 250mics or more

Exclusion Criteria:

• Previous treatment.

• Other ophthalmic diseases. history of Nephropathy, heart diseases and pregnancy

• Media opacities